Assembly Biosciences (ASMB)

• Market cap: $435M
• 1 day: -4.7%
• 5 days: 2.62%
• 1 month: -0.44%
• 3 months: -8.18%
• 6 months: -27.49%
• Year to date: -18.81%
• 1 year: 94.33%
• 5 years: -42.19%
• 10 years: -57.56%
• Sector: Healthcare
• Industry: Biotechnology

About: Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Employees: 73